The Drugs Controller General of India (DCGI) has formally announced the final approval for Oxford-AstraZeneca “Covishield” and Bharat Biotech “Covaxin” vaccines against the coronavirus disease (Covid-19) for emergency use. CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines.
About Covishield:
The subject expert committee (SEC) under CDSCO had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.
About Covaxin:
Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Important takeaways for all competitive exams:
India’s largest airline, IndiGo, has witnessed widespread flight cancellations and delays, affecting thousands of travellers…
The world is entering a new technological era — one where quantum computing, quantum communication…
The World Meteorological Organization (WMO) has issued its latest ENSO (El Niño–Southern Oscillation) Update, predicting…
Marking its 25th anniversary, IFFCO-TOKIO General Insurance Company (GIC) announced a new initiative aimed at…
New York-based AI company Runway has launched Gen-4.5, its most advanced text-to-video generation model to…
Following good monsoon rains, migratory birds like storks, pelicans, painted storks, and bar-headed geese have…